Analysis of the key themes driving M&A activity reveals that artificial intelligence accounted for 11 pharmaceutical deals announced in Q3 2024, worth a total value of $1.7bn. The $1.1bn acquisition of Integrated Oncology Network by Cardinal Health was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, artificial intelligence-related deal activity increased by 310% in Q3 2024 compared with the previous quarter’s total of $414.5m and rose by 1534% as compared to Q3 2023. Related deal volume decreased by 45% in Q3 2024 versus the previous quarter and was 21% lower than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in 9M 2024 were Allen & Overy; BDA Partners; Centerview Partners with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in 9M 2024 were Meitar Law Offices; Ropes & Gray; Eversheds Sutherland (International) with 2, 2, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.